More good news for AZ with priority review for non-Hodgkin's lymphoma drug

2 August 2017
2019_biotech_test_vial_discovery_big

Following yesterday’s news that the US Food and Drug administration had granted breakthrough status to acalabrutinib, London-listed AstraZeneca (LSE: AZN) has announced the drug has also been accepted for priority review by the American regulator.

Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor that has undergone a Phase II clinical trial in relapsed/refractory mantle cell lymphoma (MCL).

The company says it will present results from the clinical trial at a forthcoming medical meeting. A decision from the US FDA is now expected in the first quarter of 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology